Although the literature has investigated the protective effect of FAAH inhibitors in the brain area, a recent study conducted with a group of 250 epilepsy individuals, 157 cases with ADHD and 386 healthy controls [26] demonstrated that reduced levels of FAAH enzyme produced by this polymorphism increased generalised epilepsy risk by approximately two times (FAAH C384A genotype, OR = 1.755, 95% CI 1.124–2.742, p = 0.013, and allele, OR 1.462, 95% CI 1.006–2.124, p = 0.046). The gene discussed is FAAH; the disease is attention deficit-hyperactivity disorder.